Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma.
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
21 04 2022
21 04 2022
Historique:
pubmed:
26
2
2022
medline:
23
4
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
Black and Latinx patients bear a disproportionate burden of asthma. Efforts to reduce the disproportionate morbidity have been mostly unsuccessful, and guideline recommendations have not been based on studies in these populations. In this pragmatic, open-label trial, we randomly assigned Black and Latinx adults with moderate-to-severe asthma to use a patient-activated, reliever-triggered inhaled glucocorticoid strategy (beclomethasone dipropionate, 80 μg) plus usual care (intervention) or to continue usual care. Participants had one instructional visit followed by 15 monthly questionnaires. The primary end point was the annualized rate of severe asthma exacerbations. Secondary end points included monthly asthma control as measured with the Asthma Control Test (ACT; range, 5 [poor] to 25 [complete control]), quality of life as measured with the Asthma Symptom Utility Index (ASUI; range, 0 to 1, with lower scores indicating greater impairment), and participant-reported missed days of work, school, or usual activities. Safety was also assessed. Of 1201 adults (603 Black and 598 Latinx), 600 were assigned to the intervention group and 601 to the usual-care group. The annualized rate of severe asthma exacerbations was 0.69 (95% confidence interval [CI], 0.61 to 0.78) in the intervention group and 0.82 (95% CI, 0.73 to 0.92) in the usual-care group (hazard ratio, 0.85; 95% CI, 0.72 to 0.999; P = 0.048). ACT scores increased by 3.4 points (95% CI, 3.1 to 3.6) in the intervention group and by 2.5 points (95% CI, 2.3 to 2.8) in the usual-care group (difference, 0.9; 95% CI, 0.5 to 1.2); ASUI scores increased by 0.12 points (95% CI, 0.11 to 0.13) and 0.08 points (95% CI, 0.07 to 0.09), respectively (difference, 0.04; 95% CI, 0.02 to 0.05). The annualized rate of missed days was 13.4 in the intervention group and 16.8 in the usual-care group (rate ratio, 0.80; 95% CI, 0.67 to 0.95). Serious adverse events occurred in 12.2% of the participants, with an even distribution between the groups. Among Black and Latinx adults with moderate-to-severe asthma, provision of an inhaled glucocorticoid and one-time instruction on its use, added to usual care, led to a lower rate of severe asthma exacerbations. (Funded by the Patient-Centered Outcomes Research Institute and others; PREPARE ClinicalTrials.gov number, NCT02995733.).
Sections du résumé
BACKGROUND
Black and Latinx patients bear a disproportionate burden of asthma. Efforts to reduce the disproportionate morbidity have been mostly unsuccessful, and guideline recommendations have not been based on studies in these populations.
METHODS
In this pragmatic, open-label trial, we randomly assigned Black and Latinx adults with moderate-to-severe asthma to use a patient-activated, reliever-triggered inhaled glucocorticoid strategy (beclomethasone dipropionate, 80 μg) plus usual care (intervention) or to continue usual care. Participants had one instructional visit followed by 15 monthly questionnaires. The primary end point was the annualized rate of severe asthma exacerbations. Secondary end points included monthly asthma control as measured with the Asthma Control Test (ACT; range, 5 [poor] to 25 [complete control]), quality of life as measured with the Asthma Symptom Utility Index (ASUI; range, 0 to 1, with lower scores indicating greater impairment), and participant-reported missed days of work, school, or usual activities. Safety was also assessed.
RESULTS
Of 1201 adults (603 Black and 598 Latinx), 600 were assigned to the intervention group and 601 to the usual-care group. The annualized rate of severe asthma exacerbations was 0.69 (95% confidence interval [CI], 0.61 to 0.78) in the intervention group and 0.82 (95% CI, 0.73 to 0.92) in the usual-care group (hazard ratio, 0.85; 95% CI, 0.72 to 0.999; P = 0.048). ACT scores increased by 3.4 points (95% CI, 3.1 to 3.6) in the intervention group and by 2.5 points (95% CI, 2.3 to 2.8) in the usual-care group (difference, 0.9; 95% CI, 0.5 to 1.2); ASUI scores increased by 0.12 points (95% CI, 0.11 to 0.13) and 0.08 points (95% CI, 0.07 to 0.09), respectively (difference, 0.04; 95% CI, 0.02 to 0.05). The annualized rate of missed days was 13.4 in the intervention group and 16.8 in the usual-care group (rate ratio, 0.80; 95% CI, 0.67 to 0.95). Serious adverse events occurred in 12.2% of the participants, with an even distribution between the groups.
CONCLUSIONS
Among Black and Latinx adults with moderate-to-severe asthma, provision of an inhaled glucocorticoid and one-time instruction on its use, added to usual care, led to a lower rate of severe asthma exacerbations. (Funded by the Patient-Centered Outcomes Research Institute and others; PREPARE ClinicalTrials.gov number, NCT02995733.).
Identifiants
pubmed: 35213105
doi: 10.1056/NEJMoa2118813
pmc: PMC10367430
mid: NIHMS1905458
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Glucocorticoids
0
Beclomethasone
KGZ1SLC28Z
Banques de données
ClinicalTrials.gov
['NCT02995733']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1505-1518Subventions
Organisme : NIAID NIH HHS
ID : K23 AI125785
Pays : United States
Organisme : Patient-Centered Outcomes Research Institute
ID : PCS-1504-30283
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI835475
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2022 Massachusetts Medical Society.
Références
J Asthma. 2011 May;48(4):405-13
pubmed: 21504353
J Allergy Clin Immunol. 2020 Dec;146(6):1217-1270
pubmed: 33280709
Br J Clin Pharmacol. 2020 Jul;86(7):1281-1288
pubmed: 31823381
Cochrane Database Syst Rev. 2017 Apr 18;4:CD012226
pubmed: 28417456
Chest. 2003 Sep;124(3):803-12
pubmed: 12970001
J Allergy Clin Immunol. 2008 Aug;122(2):313-8
pubmed: 18538382
Lancet. 2006 Aug 26;368(9537):744-53
pubmed: 16935685
J Allergy Clin Immunol. 2012 Nov;130(5):1078-84
pubmed: 23026499
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Contemp Clin Trials. 2021 Feb;101:106246
pubmed: 33316456
Clin Rev Allergy Immunol. 2012 Aug;43(1-2):156-83
pubmed: 21538075
PLoS One. 2016 Jun 13;11(6):e0157301
pubmed: 27294365
Chest. 2009 Oct;136(4):1063-1071
pubmed: 19567492
N Engl J Med. 1992 Feb 20;326(8):501-6
pubmed: 1346340
J Allergy Clin Immunol. 2004 Jan;113(1):59-65
pubmed: 14713908
Clin Chest Med. 2019 Mar;40(1):163-177
pubmed: 30691710
Am J Public Health. 2006 Feb;96(2):358-62
pubmed: 16380574
Ann Am Thorac Soc. 2018 Mar;15(3):348-356
pubmed: 29323930
J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1
pubmed: 19767070
JAMA. 2012 Sep 12;308(10):987-97
pubmed: 22968888
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2896-2899.e1
pubmed: 33940216
JAMA. 2015 Oct 27;314(16):1720-30
pubmed: 26505596
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):504-9
pubmed: 10673193
J Allergy Clin Immunol. 2009 May;123(5):1077-82, 1082.e1-5
pubmed: 19230959
J Asthma. 2003 Jun;40(4):367-73
pubmed: 12870832
J Allergy Clin Immunol Pract. 2022 Feb;10(2):517-524.e2
pubmed: 34673286
Am J Respir Crit Care Med. 2007 Apr 15;175(8):783-90
pubmed: 17204725
J Allergy Clin Immunol. 2006 Mar;117(3):549-56
pubmed: 16522452
J Allergy Clin Immunol. 2006 Feb;117(2):351-8
pubmed: 16461136
Chest. 1998 Oct;114(4):998-1007
pubmed: 9792568
Annu Rev Public Health. 2005;26:89-113
pubmed: 15760282
Ann Allergy Asthma Immunol. 2020 May;124(5):487-493.e1
pubmed: 31923550
J Gen Intern Med. 2012 Aug;27(8):1001-15
pubmed: 22798212
J Health Commun. 2012;17 Suppl 3:141-59
pubmed: 23030567
Allergy. 2007 Jun;62(6):655-60
pubmed: 17508970
Am J Respir Crit Care Med. 2009 Jul 1;180(1):59-99
pubmed: 19535666